RPH-104 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
266	Familial mediterranean fever	2

266. Familial mediterranean fever

---

Clinical trials : 28 /  Drugs : 22 - (DrugBank : 5) / Drug target genes : 14 - Drug target pathways : 59

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05190991 (ClinicalTrials.gov)	October 5, 2021	3/11/2021	Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever	An International Multicenter Open-label Clinical Study of the Safety and Efficacy of RPH-104 for Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine	Familial Mediterranean Fever;FMF	Biological: RPH-104	R-Pharm International, LLC	Atlant Clinical LLC;Center for Pharmaceutical Analytics LLC;Unimed Laboratories CJSC;Data Management 365	Recruiting	18 Years	80 Years	All	60	Phase 2	Armenia;Georgia;Russian Federation
2	NCT05092776 (ClinicalTrials.gov)	April 29, 2021	9/9/2021	Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine	International, Multicenter, Double Blind, Placebo-controlled, Randomized Clinical Study of Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine	Familial Mediterranean Fever;FMF	Biological: RPH-104;Drug: Placebo	R-Pharm International, LLC	Data Management 365;Atlant Clinical LLC;R-Pharm;Center of Pharmaceutical Analytics LLC;Unimed Laboratories CJSC	Recruiting	18 Years	N/A	All	60	Phase 2	Armenia;Georgia;Russian Federation